

Table SI. Patient characteristics.

Paramater	ER+/PR+/RAB6C+			ER+/PR+/RAB6C-			ER+/PR-/RAB6C+			ER+/PR-/RAB6C-		
	TAM-	TAM+	P-value	TAM-	TAM+	P-value	TAM-	TAM+	P-value	TAM-	TAM+	P-value
Total no. of patients	75 (40)	111 (60)		68 (51)	66 (49)		41 (53)	37 (47)		43 (49)	45 (51)	
Age												
≤60	32 (44)	41 (56)	0.43	37 (60)	25 (40)	0.06	17 (50)	17 (50)	0.69	13 (46)	15 (54)	0.76
>60	43 (38)	70 (61)		31 (43)	41 (57)		24 (55)	20 (45)		30 (50)	30 (50)	
Tumor size (mm)												
<20	66 (43)	89 (57)	0.30	52 (47)	58 (53)	0.07	32 (50)	32 (50)	0.45	30 (48)	32 (52)	0.97
≥20	9 (32)	19 (68)		15 (68)	7 (32)		8 (62)	5 (38)		12 (48)	13 (52)	
Unknown	0	3		1	1		1	0		1	0	
HER2												
Negative	72 (42)	101 (58)	0.33	62 (50)	63 (50)	0.67	32 (49)	33 (51)	0.26	34 (47)	38 (53)	0.66
Positive	1 (20)	4 (80)		2 (40)	3 (60)		5 (71)	2 (29)		7 (54)	6 (46)	
Unknown	2	6		4	0		4	2		2	1	
NHG												
I	22 (51)	21 (49)	0.41	11 (48)	12 (52)	0.95	13 (65)	7 (35)	0.17	6 (40)	9 (60)	0.35
II	44 (40)	67 (60)		34 (49)	36 (51)		18 (42)	25 (58)		29 (57)	22 (43)	
III	5 (38)	8 (62)		12 (52)	11 (48)		4 (67)	2 (33)		7 (41)	10 (59)	
Unknown	4	15		11	7		6	3		1	4	

HER2, human epidermal growth factor 2; NHG, Nottingham Histologic Grade; TAM, tamoxifen; ER, estrogen receptor; PR, progesterone receptor; RAB6C, Ras-related protein Rab-6C.